TREATMENT GOALS AND OPTIONS IN METASTATIC SOFT-TISSUE SARCOMA: CASES AND CONUNDRUMS

WEDNESDAY, 7 FEBRUARY 2018, 14:20-15:20

MILAN MARRIOTT HOTEL, VIA WASHINGTON 66, MILAN, ITALY | ROOM: SALONE WASHINGTON A

In this interactive, case-based symposium, leading experts will discuss best practices for the treatment and management of non-gastrointestinal stromal tumor (GIST) soft-tissue sarcoma (STS)

PROGRAM AGENDA

14:20 - 14:25

Introduction

William D. Tap, MD

14:25 - 14:45

Case 1: Patient With Advanced Non-GIST STS Who Did Not Receive Prior Doxorubicin Jean-Yves Blay, MD, PhD

14:45 - 15:05

Case 2: Patient With Advanced Non-GIST STS Who Did Receive Prior Doxorubicin Robin L. Jones, BSc, MB BS, MRCP, MD

15:05 - 15:15 **Panel Discussion**

15:15 - 15:20 Closing Remarks

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
 - Current unmet needs of patients with non-GIST STS
 - Key patient selection criteria to optimize therapeutic risk-benefit of available treatment options
- · Have greater competence related to
 - Selecting treatments appropriate to patient needs and goals of therapy
 - Identifying and managing emerging adverse events of treatment to optimize patient quality of life



MODERATOR



William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center New York, New York, United States



FACULTY

Jean-Yves Blay, MD, PhD **Professor of Medical Oncology** University Claude Bernard Director Department of Medicine Centre Léon Bérard





Robin L. Jones, BSc, MB, BSc, MRCP, MD

Consultant Oncologist Royal Marsden Hospital London, United Kingdom



